Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.52 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987223 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.75 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL6964514 | 0.73 | KDM4E (0.52) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL446289 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL2050847 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL291121 | 0.71 | KDM4E (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL329419 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL11654916 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL4204967 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL18410587 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908926-B1 | Substituted imidazoles, their preparation and use | NOVO NORDISK A/S (DK) | 2005-06-21 | — | — | US | claimed |
| US-5512588-A | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-30 | — | — | US | claimed |
| US-5371097-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-06 | — | — | US | claimed |
| US-5364871-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-15 | — | — | US | claimed |
| EP-0355612-B1 | Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | EP | claimed |
| US-5308857-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-03 | — | — | US | claimed |
| EP-0417751-A2 | New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-03-20 | — | — | EP | claimed |
| EP-0355612-A2 | Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | claimed |
| US-10077254-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059233-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2009141065-A2 | (1,2-BENZISOTHIAZOL-3-YL)(THIO)CARBAMATES AND (1,2-BENZISOTHIAZOL-3-YL)(THIO)OXAMATES AND THE OXIDATION FORMS THEREOF FOR USE AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2009-11-26 | — | — | WO | disclosed |
| US-5371097-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0355612-B1 | Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5308857-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0417751-A2 | New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-03-20 | — | — | EP | disclosed |
| EP-0355612-A2 | Furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| EP-0105732-A3 | HISTAMINE H2 RECEPTOR ANTAGONISTS OF THE BENZISOTHIAZOLE AMINO AND BENZTHIADIAZINE AMINO SERIES | BEECHAM GROUP PLC (GB) | 1985-09-04 | — | — | EP | disclosed |
| EP-0105732-A2 | Histamine H2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series | BEECHAM GROUP PLC (GB) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077254-B2 | Tetrazolinone compound and use thereof | MT-CO1, UQCRB, MT-CO2 | MAPT 3682/4885KDM4E 2469/4885ALDH1A1 1465/4885 |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MT-CO1, UQCRB, MT-CO2 | MAPT 3682/4885KDM4E 2469/4885ALDH1A1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.